Patents Assigned to Massachusetts Eye and Ear Infirmary
  • Patent number: 10420826
    Abstract: Compositions comprising antigenic peptides, and their use in inducing an immunoprotective response in a subject against an infection with Streptococcus pneumonia, or for treating or preventing, i.e., reducing risk of, an infection of Streptococcus pneumonia.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: September 24, 2019
    Assignee: Massachusetts Eye & Ear Infirmary
    Inventors: Michael Valentino, Michael S. Gilmore
  • Patent number: 10413518
    Abstract: Methods for reducing angiogenesis, inflammation, and vascular permeability in a subject by administering an epoxymetabolite of Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA), e.g., as listed in Table A, e.g., one or both of 17,18-epoxyeicosatetraenoic acid (EEQ) and 19,20-epoxydocosapentaenoic acid (EDP), e.g., for the treatment of conditions associated with inflammation or excess angiogenesis or neovascularization, including age-related macular degeneration, cancer, stroke, and arthritis.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: September 17, 2019
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Kip M. Connor, Ryoji Yanai
  • Publication number: 20190276529
    Abstract: Methods of treating acute thyroid eye disease (TED) by administering a inhibitor, e.g., a VEGF-A inhibitor, e.g., an anti-VEGF antibody, optionally in combination with hyaluronidase, by periorbital or intraorbital injection. Also compositions comprising a VEGF inhibitor and hyaluronidase.
    Type: Application
    Filed: June 8, 2017
    Publication date: September 12, 2019
    Applicants: Massachusetts Eye and Ear Infirmary
    Inventors: N. Grace LEE, Leo KIM, Patricia A. D`AMORE, James A. STEFATER
  • Patent number: 10406163
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: September 10, 2019
    Assignees: Massachusetts Eye & Ear Infirmary, The Brigham & Women's Hospital, Inc.
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • Publication number: 20190224375
    Abstract: The invention provides methods and polymer compositions for treating retinal detachment and other ocular disorders, where the methods employ polymer compositions that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (i) a nucleo-functional polymer that is a biocompatible polymer containing a plurality of thio-functional groups —R1—SH wherein R1 is an ester-containing linker, such as a thiolated poly(vinyl alcohol) polymer and (ii) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups.
    Type: Application
    Filed: July 13, 2017
    Publication date: July 25, 2019
    Applicant: Massachusetts Eye and Ear Infirmary
    Inventors: James Anthony STEFATER, III, Tomasz Pawel STRYJEWSKI
  • Publication number: 20190175791
    Abstract: The invention provides methods and polymer compositions for treating retinal detachment and other ocular disorders, where the methods employ polymer compositions that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (i) a nucleo-functional polymer that is a biocompatible polymer containing a plurality of thio-functional groups —R1—SH wherein R1 is an ester-containing linker, such as a thiolated poly(vinyl alcohol) polymer and (ii) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups.
    Type: Application
    Filed: January 11, 2019
    Publication date: June 13, 2019
    Applicant: Massachusetts Eye and Ear Infirmary
    Inventors: James Anthony STEFATER, III, Tomasz Pawel STRYJEWSKI
  • Patent number: 10314924
    Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: June 11, 2019
    Assignees: Massachusetts Eye & Ear Infirmary, UCL Business PLC, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Michael A. Sandberg, Basil Pawlyk, Alan Finlay Wright, Xinhua Shu, Tiansen Li, Robin Ali
  • Publication number: 20190160445
    Abstract: The present invention generally relates to microfluidic droplets and, including forming gels within microfluidic droplets. In some aspects, a fluid containing agarose or other gel precursors is transported into a microfluidic droplet, and caused to harden within the droplet, e.g., to form a gel particle contained within the microfluidic droplet. Surprisingly, a discrete gel particle may be formed even if the fluid containing the agarose or other gel precursor, and the fluid contained within the microfluidic droplet, are substantially immiscible. Other aspects of the present invention are generally directed to techniques for making or using such gels within microfluidic droplets, kits containing such gels within microfluidic droplets, or the like.
    Type: Application
    Filed: July 7, 2017
    Publication date: May 30, 2019
    Applicants: President and Fellows of Harvard College, Massachusetts Eye and Ear Infirmary
    Inventors: David A. Weitz, Huidan Zhang, Nai Wen Cui, Fengyang Lei, Eleftherios Paschalis llios
  • Patent number: 10272089
    Abstract: The use of methotrexate, e.g., repeated dosing or sustained-release formulations of methotrexate, for treating or reducing risk of proliferative vitreoretinopathy (PVR) or epiretinal membranes (ERM), e.g., after surgical vitrectomy to treat retinal detachment.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: April 30, 2019
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Dean Eliott, Tomasz P. Stryjewski
  • Patent number: 10272261
    Abstract: The invention provides a photodynamic therapy-based method for treating ocular glaucoma. A photosensitizer, for example, a benzoporphyrin derivative photosensitizer, is administered to a mammal either having or at risk of developing ocular glaucoma. The photosensitizer, when present in the ciliary body, is activated by light, for example, light from a laser. The treatment results in a reduction of intraocular pressure within the treated eye, which can persist for a prolonged period of time.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: April 30, 2019
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Joan W. Miller, Akihisa Matsubara, Deeba Husain, Evangelos S. Gragoudas
  • Patent number: 10258668
    Abstract: The present invention relates to methods to treat a neurodegenerative disease or disorder, e.g., a motor neuron disease in a subject, whereby the subject is administered a recombinant human Mullerian Inhibiting Substance (MIS) protein as disclosed herein, wherein the recombinant human MIS protein comprises a modified Kex cleavage site for increased cleavage. The recombinant human MIS protein can be produced from a pre-proprotein comprising a non-MIS leader sequence or a functional fragment thereof in place of the MIS leader sequence.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 16, 2019
    Assignees: The General Hospital Corporation, Massachusetts Eye and Ear Infirmary, University of Massachusetts
    Inventors: Patricia K. Donahoe, Demetrios Vavvas, David Pepin, Mien Van Hoang, Robert H. Brown, Jr., Guangping Gao
  • Patent number: 10258697
    Abstract: Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: April 16, 2019
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Zheng-Yi Chen, David Liu, John Anthony Zuris, David B. Thompson
  • Patent number: 10222444
    Abstract: A magnetic resonance imaging (“MRI”) system that can be operated while a subject performs, experiences, or otherwise undergoes naturalistic motion. This movable MRI (“mMRI”) system includes a magnet whose position and orientation can be changed while the subject is moving, such that the magnet and subject maintain a substantially fixed spatial relationship relative to each other.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: March 5, 2019
    Assignees: The General Hospital Corporation, Massachusetts Eye and Ear Infirmary
    Inventors: Daniel Merfeld, Jerome Ackerman
  • Publication number: 20190046029
    Abstract: Disclosed are a mobile device and method which include acquiring, by an image acquisition unit installed in a mobile device, an image of eyes of a patient while light provided by a light source reflects from an optical surface of the eyes of the patient; and obtaining, by a processor installed in the mobile device, ocular misalignment measurements, including a magnitude and a direction of ocular misalignment in the eyes of the patient, using the acquired image or set of images.
    Type: Application
    Filed: February 16, 2017
    Publication date: February 14, 2019
    Applicant: Massachusetts Eye and Ear Infirmary
    Inventors: Matteo Tomasi, Shrinivas Pundlik, Kevin Edward Houston, Gang Luo
  • Publication number: 20190022101
    Abstract: Methods of treating or reducing the risk of developing hidden hearing loss by administering a small molecule Trk agonists (e.g., amitriptyline, imipramine, LM 22A4 (N,N?,N?Tris(2-hydroxyethyl)-1,3,5-benzenetricarboxamide), 7, 8-dihydroxyflavone (DHF), 7,8,3?-Trihydroxyflavone (THF), Mab2256, neurotrophin-4 (NT-4), neurotrophin-3 (NT-3), brain derived neurotrophic factor (BDNF), nerve growth factor (NGF), N-acetylserotonin, N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]-2-oxo-3-piperidinecarboxamide (HIOC), deoxygedunin, LM-22A4, or tricyclic dimeric peptide 6 (TDP6)).
    Type: Application
    Filed: January 6, 2017
    Publication date: January 24, 2019
    Applicant: Massachusetts Eye and Ear Infirmary
    Inventors: Sharon Kujawa, Albert Edge, M. Charles Liberman
  • Publication number: 20190022280
    Abstract: The present invention provides compositions and methods for repair and reconstruction of defects and injuries to the cornea.
    Type: Application
    Filed: February 8, 2017
    Publication date: January 24, 2019
    Applicants: The Brigham and Women's Hospital, Inc., Massachusetts Eye and Ear Infirmary
    Inventors: Ali KHADEMHOSSEINI, Nasim ANNABI, Reza DANA, Ahmad KHEIRKHAH
  • Publication number: 20190022383
    Abstract: Methods and devices are provided for electrical neural blockade and stimulation of dysfunctional or transferred nerves. For example, a method is provided including identifying a dysfunctional or transferred nerve, attaching an electrode array to the dysfunctional or transferred nerve proximal to the target musculature, delivering an electrical neural blockade signal, and stimulating the dysfunctional or transferred nerve distal to the point of neural blockade. A system is also provided with an electrode array configured to attach proximally to a dysfunctional or transferred nerve and deliver an electrical neural blockade signal with a neuromuscular stimulating electrode array placed distal to the point of neural blockade, and a processor in communication with the electrode arrays and configured to provide stimulation instructions based on the detected activity of the other neuromusculature.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 24, 2019
    Applicant: Massachusetts Eye and Ear Infirmary
    Inventors: Theresa A. Hadlock, Nathan T. P. Jowett
  • Publication number: 20190015035
    Abstract: Apparatus and methods for estimating a vestibular function of a subject include a motion platform for supporting a subject and an input device configured to receive confidence ratings from the subject. The motion platform is configured to execute one or more motions. The confidence ratings are related to the subject's perception of the one or more motions. The apparatus further includes a processer configured to fit a cumulative distribution function to the confidence ratings, determine a relationship configured to link the cumulative distribution function to an underlying noise distribution, and output parameters associated with the vestibular function based at least in part on the relationship.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 17, 2019
    Applicant: Massachusetts Eye and Ear Infirmary
    Inventors: Daniel Michael MERFELD, Yongwoo YI
  • Patent number: 10149884
    Abstract: Provided are methods and compositions for maintaining the viability of photoreceptor cells and/or retinal pigment epithelial cells in a subject with an ocular disorder including, for example, age-related macular degeneration (AMD) (e.g., dry or neovascular AMD), retinitis pigmentosa (RP), or a retinal detachment. The viability of the photoreceptor cells and/or the retinal pigment epithelial cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells, thereby minimizing the loss of vision or visual function associated with the ocular disorder.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 11, 2018
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Demetrios Vavvas, Georgios Trichonas, Joan W. Miller, Yusuke Murakami
  • Patent number: 10143703
    Abstract: Methods of treating ocular neovascularization, e.g., associated with wet agerelated macular degeneration (AMD), using activators of AMP-activated protein kinase (AMPK) and/or of Phosphatase and tensin homolog deleted on chromosome 10 (PTEN).
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: December 4, 2018
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Demetrios Vavvas, Joan W. Miller, Kimio Takeuchi